Rep. Gilbert Ray Cisneros, Jr. Buys The Cooper Companies, Inc. (NASDAQ:COO) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of The Cooper Companies, Inc. (NASDAQ:COO). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cooper Companies stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
• Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.

Cooper Companies Price Performance

Cooper Companies stock traded down $0.93 during mid-day trading on Wednesday, reaching $67.69. 3,013,405 shares of the company were exchanged, compared to its average volume of 2,362,111. The firm has a market cap of $13.20 billion, a PE ratio of 57.36, a PEG ratio of 1.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The company has a fifty day simple moving average of $64.97 and a 200-day simple moving average of $74.48. The Cooper Companies, Inc. has a 12 month low of $58.89 and a 12 month high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the firm posted $0.96 EPS. Cooper Companies’s quarterly revenue was up 7.9% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on COO shares. Citigroup reaffirmed a “neutral” rating and set a $69.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday, May 28th. Weiss Ratings cut Cooper Companies from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. Piper Sandler set a $86.00 target price on Cooper Companies and gave the company an “overweight” rating in a report on Monday, June 1st. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research note on Wednesday, May 27th. Finally, Barclays upped their price objective on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $82.64.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Recent analyst and research commentary continues to frame Cooper Companies as a growth story, with articles highlighting strong demand trends and the potential for a future rating upgrade as valuation becomes more attractive. The Cooper Companies: I Can See A Potential Upgrade On The Horizon
• Positive Sentiment: Another recent analysis said Cooper Companies delivered an earnings beat and continued demand growth, reinforcing the view that core operations remain healthy despite margin concerns. Cooper Companies: Demand Growth And Earnings Beat, Needs Stronger ROE And Profit Margins
• Neutral Sentiment: A Zacks piece also argued that The Cooper Companies (COO) remains a strong long-term growth stock, which may help support the shares but does not add a new immediate catalyst. Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term
• Negative Sentiment: Investor caution remains elevated because one recent note flagged litigation risk and only mixed profitability, with embryo culture media recall charges weighing on reported earnings. The Cooper Companies: I Can See A Potential Upgrade On The Horizon
• Negative Sentiment: A recent SEC-related filing showed a company insider sold about $828,000 of AMR stock, which may add a bit of near-term overhang sentiment for COO investors. COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing

Institutional Trading of Cooper Companies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital World Investors boosted its stake in shares of Cooper Companies by 25.7% in the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after purchasing an additional 2,159,233 shares during the last quarter. State Street Corp lifted its holdings in Cooper Companies by 2.4% in the fourth quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after buying an additional 207,195 shares during the period. Wellington Management Group LLP boosted its position in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after acquiring an additional 4,756,178 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after acquiring an additional 2,231,568 shares during the last quarter. Finally, Sustainable Growth Advisers LP grew its holdings in Cooper Companies by 22.1% during the 3rd quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock worth $283,327,000 after acquiring an additional 747,476 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.